上海医药
(601607)
| 流通市值：500.10亿 | | | 总市值：664.91亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 36,731,758,748.4 | 39,094,785,250.94 | 36,166,579,289.29 | 35,744,328,038.57 |
| 交易性金融资产 | 7,816,270,273.97 | 8,404,903,589.04 | 8,863,933,150.68 | 8,632,930,000 |
| 衍生金融资产 | 994,853.52 | 4,918,514.43 | 17,813,362.18 | 16,224,786.35 |
| 应收票据及应收账款 | 89,848,665,692.43 | 87,219,561,553.39 | 86,342,937,481.74 | 80,251,310,784.39 |
| 其中：应收票据 | 1,065,609,050.48 | 841,716,223.13 | 988,493,324.15 | 1,122,105,045.23 |
| 应收账款 | 88,783,056,641.95 | 86,377,845,330.26 | 85,354,444,157.59 | 79,129,205,739.16 |
| 应收款项融资 | 1,668,551,993.81 | 1,911,121,780.41 | 1,666,015,677.26 | 1,965,669,770.02 |
| 预付款项 | 2,099,544,705.72 | 2,652,933,938.8 | 2,162,409,791.51 | 1,947,402,427.71 |
| 其他应收款合计 | 2,892,025,630.93 | 3,076,379,090.27 | 3,252,917,089.39 | 3,106,695,609.03 |
| 应收股利 | 24,812,649.82 | 8,012,649.82 | 99,097,336.55 | 94,189,935.96 |
| 存货 | 41,783,787,540.93 | 40,899,076,963.47 | 37,816,903,996.22 | 38,943,669,737.08 |
| 一年内到期的非流动资产 | 53,100,734.44 | 59,048,697.08 | 70,056,573.14 | 83,611,615.14 |
| 其他流动资产 | 1,033,573,215.36 | 1,134,024,657.5 | 952,135,663.38 | 1,131,264,653.68 |
| 流动资产合计 | 183,928,273,389.51 | 184,456,754,035.33 | 177,311,702,074.79 | 171,823,107,421.97 |
| 非流动资产: | | | | |
| 长期应收款 | 332,460,022.77 | 342,376,568.05 | 392,244,518.27 | 386,244,506.89 |
| 长期股权投资 | 7,024,473,181.92 | 6,895,330,823.14 | 7,182,247,645.21 | 8,066,844,872.89 |
| 其他权益工具投资 | 37,904,676.94 | 34,537,342.18 | 46,595,116.03 | 43,899,340.7 |
| 其他非流动金融资产 | 1,500,578,595.7 | 1,717,717,621.06 | 1,815,729,571.1 | 1,724,668,131.23 |
| 投资性房地产 | 378,436,621.72 | 422,069,186.59 | 355,960,318.61 | 366,010,300.23 |
| 固定资产 | 14,691,331,801.29 | 14,951,135,063.63 | 14,674,269,190.73 | 14,911,045,205.84 |
| 在建工程 | 2,475,535,410.2 | 2,382,163,131.76 | 2,304,076,819.25 | 2,148,651,608.6 |
| 生产性生物资产 | 4,615,299.69 | 8,461,853.96 | 132,380,893.58 | 133,381,840.87 |
| 使用权资产 | 1,823,101,868.08 | 1,895,536,449.93 | 2,039,032,207.48 | 1,981,731,618.35 |
| 无形资产 | 8,938,603,644.35 | 9,164,485,474.51 | 5,572,571,979.25 | 5,617,462,430.33 |
| 开发支出 | 220,546,205.27 | 222,370,286.93 | 184,558,970.42 | 215,324,899.96 |
| 商誉 | 12,735,504,562.05 | 12,836,417,573.07 | 11,118,507,730.51 | 11,145,586,135.68 |
| 长期待摊费用 | 540,670,515.05 | 556,439,540.26 | 522,000,456.82 | 534,566,477.24 |
| 递延所得税资产 | 1,733,733,678.37 | 1,718,921,891.13 | 1,768,158,553.08 | 1,627,529,013.21 |
| 其他非流动资产 | 380,475,763.31 | 462,339,229.84 | 451,855,644.68 | 483,376,344.18 |
| 非流动资产合计 | 52,817,971,846.71 | 53,610,302,036.04 | 48,560,189,615.02 | 49,386,322,726.2 |
| 资产总计 | 236,746,245,236.22 | 238,067,056,071.37 | 225,871,891,689.81 | 221,209,430,148.17 |
| 流动负债: | | | | |
| 短期借款 | 44,490,364,239.86 | 45,621,718,368.07 | 42,909,928,847.57 | 38,064,098,967.71 |
| 衍生金融负债 | 10,957,111.95 | 3,289,903.19 | 1,962,253.82 | 1,598,178.46 |
| 应付票据及应付账款 | 64,548,321,208.76 | 63,011,635,851.42 | 60,374,595,560.13 | 59,482,920,479.29 |
| 其中：应付票据 | 7,890,743,469.52 | 7,112,113,974.4 | 8,201,521,517.98 | 9,241,133,347.89 |
| 应付账款 | 56,657,577,739.24 | 55,899,521,877.02 | 52,173,074,042.15 | 50,241,787,131.4 |
| 合同负债 | 1,304,859,343.17 | 1,212,865,778.27 | 1,292,454,333.52 | 1,562,036,773.57 |
| 应付职工薪酬 | 1,834,704,586.61 | 1,564,385,094.13 | 1,282,248,300.11 | 1,796,347,060.73 |
| 应交税费 | 1,381,921,817.49 | 1,239,722,518.23 | 1,358,878,153.13 | 1,264,015,312.92 |
| 其他应付款合计 | 16,322,460,744.02 | 17,889,183,683.53 | 15,139,403,273.4 | 16,797,359,516.09 |
| 应付股利 | 624,228,265.18 | 1,710,839,497.1 | 235,507,702.06 | 381,062,451.26 |
| 一年内到期的非流动负债 | 3,903,432,558.78 | 3,423,071,751.58 | 2,216,509,346.55 | 842,162,528.36 |
| 其他流动负债 | 5,193,226,292.03 | 6,165,149,161.23 | 6,237,154,799.59 | 6,227,847,461.97 |
| 流动负债合计 | 138,990,247,902.67 | 140,131,022,109.65 | 130,813,134,867.82 | 126,038,386,279.1 |
| 非流动负债: | | | | |
| 长期借款 | 4,120,516,630.15 | 4,698,141,763.96 | 6,620,048,311.11 | 8,331,334,115.57 |
| 租赁负债 | 1,200,491,502.18 | 1,409,387,957.81 | 1,462,392,221.1 | 1,396,299,515.58 |
| 长期应付款 | - | - | 11,724,960.61 | 9,153,417.88 |
| 长期应付职工薪酬 | 61,237,650.7 | 56,795,866.12 | 35,952,724.81 | 39,161,175.37 |
| 预计负债 | 30,930,879.85 | 38,768,731.17 | 36,515,601.66 | 36,025,175.59 |
| 递延收益 | 528,973,653.19 | 603,627,624.16 | 543,953,280.65 | 550,991,222.67 |
| 递延所得税负债 | 1,916,531,484.47 | 2,023,974,550.06 | 788,187,449.88 | 816,452,826.21 |
| 其他非流动负债 | 274,691,694.9 | 247,432,904.79 | 259,012,989.6 | 249,262,699.13 |
| 非流动负债合计 | 8,133,373,495.44 | 9,078,129,398.07 | 9,757,787,539.42 | 11,428,680,148 |
| 负债合计 | 147,123,621,398.11 | 149,209,151,507.72 | 140,570,922,407.24 | 137,467,066,427.1 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,708,361,809 | 3,708,361,809 | 3,708,361,809 | 3,707,971,839 |
| 资本公积 | 29,701,717,860.25 | 29,695,514,631.31 | 29,655,596,049.54 | 29,647,771,271.51 |
| 其他综合收益 | -537,313,358.28 | -530,117,954.13 | -540,459,594.5 | -534,279,925.88 |
| 盈余公积 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 |
| 未分配利润 | 40,603,144,710.02 | 39,914,944,653.52 | 37,880,277,857.19 | 36,547,207,403.71 |
| 归属于母公司股东权益合计 | 75,782,860,404.62 | 75,095,652,523.33 | 73,010,725,504.86 | 71,675,619,971.97 |
| 少数股东权益 | 13,839,763,433.49 | 13,762,252,040.32 | 12,290,243,777.71 | 12,066,743,749.1 |
| 股东权益合计 | 89,622,623,838.11 | 88,857,904,563.65 | 85,300,969,282.57 | 83,742,363,721.07 |
| 负债和股东权益合计 | 236,746,245,236.22 | 238,067,056,071.37 | 225,871,891,689.81 | 221,209,430,148.17 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-29 | 2025-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |